<h4>Background</h4>The prognostic value of longitudinal antinuclear antibody (ANA) dynamics in rheumatoid arthritis (RA) remains unclear.<h4>Objectives</h4>To examine whether ANA development (titer rise/seroconversion) is associated with 12-month clinical remission and to develop a prediction model for DAS28-CRP remission.<h4>Methods</h4>We retrospectively enrolled 688 adults with RA (2010 criteria) from 2016-2023. This evidence concerns the gene CRP and rheumatoid arthritis.